Compare IBI305 and Bevacizumab on Pharmacokinetics/Safety/Immunogenicity on Healthy Male

NCT03083990 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

BIOLOGICAL: IBI305(Bevacizumab Biosimilar)
DRUG: Avastin(Bevacizumab)

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.